Cargando…

Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression

BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that lacks targeted therapies. Patients with TNBC have a very poor prognosis because the disease often metastasizes. New treatment approaches addressing drivers of metastasis and tumor growth are crucial to impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jihyun, Tacam, Moises J., Chauhan, Gaurav, Cohen, Evan N., Gagliardi, Maria, Iles, Lakesla R., Ueno, Naoto T., Battula, Venkata L., Sohn, Yoo-Kyoung, Wang, Xiaoping, Kim, Hak-Sung, Krishnamurthy, Savitri, Fowlkes, Natalie W., Green, Morgan M., Bartholomeusz, Geoffrey A., Tripathy, Debu, Reuben, James M., Bartholomeusz, Chandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357760/
https://www.ncbi.nlm.nih.gov/pubmed/34241740
http://dx.doi.org/10.1007/s10549-021-06316-2
_version_ 1783737199952396288
author Park, Jihyun
Tacam, Moises J.
Chauhan, Gaurav
Cohen, Evan N.
Gagliardi, Maria
Iles, Lakesla R.
Ueno, Naoto T.
Battula, Venkata L.
Sohn, Yoo-Kyoung
Wang, Xiaoping
Kim, Hak-Sung
Krishnamurthy, Savitri
Fowlkes, Natalie W.
Green, Morgan M.
Bartholomeusz, Geoffrey A.
Tripathy, Debu
Reuben, James M.
Bartholomeusz, Chandra
author_facet Park, Jihyun
Tacam, Moises J.
Chauhan, Gaurav
Cohen, Evan N.
Gagliardi, Maria
Iles, Lakesla R.
Ueno, Naoto T.
Battula, Venkata L.
Sohn, Yoo-Kyoung
Wang, Xiaoping
Kim, Hak-Sung
Krishnamurthy, Savitri
Fowlkes, Natalie W.
Green, Morgan M.
Bartholomeusz, Geoffrey A.
Tripathy, Debu
Reuben, James M.
Bartholomeusz, Chandra
author_sort Park, Jihyun
collection PubMed
description BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that lacks targeted therapies. Patients with TNBC have a very poor prognosis because the disease often metastasizes. New treatment approaches addressing drivers of metastasis and tumor growth are crucial to improving patient outcomes. Developing targeted gene therapy is thus a high priority for TNBC patients. PEA15 (phosphoprotein enriched in astrocytes, 15 kDa) is known to bind to ERK, preventing ERK from being translocated to the nucleus and hence blocking its activity. The biological function of PEA15 is tightly regulated by its phosphorylation at Ser104 and Ser116. However, the function and impact of phosphorylation status of PEA15 in the regulation of TNBC metastasis and in epithelial-to-mesenchymal transition (EMT) are not well understood. METHODS: We established stable cell lines overexpressing nonphosphorylatable (PEA15-AA) and phospho-mimetic (PEA15-DD) mutants. To dissect specific cellular mechanisms regulated by PEA15 phosphorylation status, we performed RT-PCR immune and metastasis arrays. In vivo mouse models were used to determine the effects of PEA15 phosphorylation on tumor growth and metastasis. RESULTS: We found that the nonphosphorylatable mutant PEA15-AA prevented formation of mammospheres and expression of EMT markers in vitro and decreased tumor growth and lung metastasis in in vivo experiments when compared to control, PEA15-WT and phosphomimetic PEA15-DD. However, phosphomimetic mutant PEA15-DD promoted migration, mesenchymal marker expression, tumorigenesis, and lung metastasis in the mouse model. PEA15-AA-mediated inhibition of breast cancer cell migratory capacity and tumorigenesis was the partial result of decreased expression of interleukin-8 (IL-8). Further, we identified that expression of IL-8 was possibly mediated through one of the ERK downstream molecules, Ets-1. CONCLUSIONS: Our results show that PEA15 phosphorylation status serves as an important regulator for PEA15’s dual role as an oncogene or tumor suppressor and support the potential of PEA15-AA as a therapeutic strategy for treatment of TNBC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-021-06316-2.
format Online
Article
Text
id pubmed-8357760
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-83577602021-08-30 Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression Park, Jihyun Tacam, Moises J. Chauhan, Gaurav Cohen, Evan N. Gagliardi, Maria Iles, Lakesla R. Ueno, Naoto T. Battula, Venkata L. Sohn, Yoo-Kyoung Wang, Xiaoping Kim, Hak-Sung Krishnamurthy, Savitri Fowlkes, Natalie W. Green, Morgan M. Bartholomeusz, Geoffrey A. Tripathy, Debu Reuben, James M. Bartholomeusz, Chandra Breast Cancer Res Treat Preclinical Study BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that lacks targeted therapies. Patients with TNBC have a very poor prognosis because the disease often metastasizes. New treatment approaches addressing drivers of metastasis and tumor growth are crucial to improving patient outcomes. Developing targeted gene therapy is thus a high priority for TNBC patients. PEA15 (phosphoprotein enriched in astrocytes, 15 kDa) is known to bind to ERK, preventing ERK from being translocated to the nucleus and hence blocking its activity. The biological function of PEA15 is tightly regulated by its phosphorylation at Ser104 and Ser116. However, the function and impact of phosphorylation status of PEA15 in the regulation of TNBC metastasis and in epithelial-to-mesenchymal transition (EMT) are not well understood. METHODS: We established stable cell lines overexpressing nonphosphorylatable (PEA15-AA) and phospho-mimetic (PEA15-DD) mutants. To dissect specific cellular mechanisms regulated by PEA15 phosphorylation status, we performed RT-PCR immune and metastasis arrays. In vivo mouse models were used to determine the effects of PEA15 phosphorylation on tumor growth and metastasis. RESULTS: We found that the nonphosphorylatable mutant PEA15-AA prevented formation of mammospheres and expression of EMT markers in vitro and decreased tumor growth and lung metastasis in in vivo experiments when compared to control, PEA15-WT and phosphomimetic PEA15-DD. However, phosphomimetic mutant PEA15-DD promoted migration, mesenchymal marker expression, tumorigenesis, and lung metastasis in the mouse model. PEA15-AA-mediated inhibition of breast cancer cell migratory capacity and tumorigenesis was the partial result of decreased expression of interleukin-8 (IL-8). Further, we identified that expression of IL-8 was possibly mediated through one of the ERK downstream molecules, Ets-1. CONCLUSIONS: Our results show that PEA15 phosphorylation status serves as an important regulator for PEA15’s dual role as an oncogene or tumor suppressor and support the potential of PEA15-AA as a therapeutic strategy for treatment of TNBC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-021-06316-2. Springer US 2021-07-09 2021 /pmc/articles/PMC8357760/ /pubmed/34241740 http://dx.doi.org/10.1007/s10549-021-06316-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Preclinical Study
Park, Jihyun
Tacam, Moises J.
Chauhan, Gaurav
Cohen, Evan N.
Gagliardi, Maria
Iles, Lakesla R.
Ueno, Naoto T.
Battula, Venkata L.
Sohn, Yoo-Kyoung
Wang, Xiaoping
Kim, Hak-Sung
Krishnamurthy, Savitri
Fowlkes, Natalie W.
Green, Morgan M.
Bartholomeusz, Geoffrey A.
Tripathy, Debu
Reuben, James M.
Bartholomeusz, Chandra
Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression
title Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression
title_full Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression
title_fullStr Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression
title_full_unstemmed Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression
title_short Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression
title_sort nonphosphorylatable pea15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of il-8 expression
topic Preclinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357760/
https://www.ncbi.nlm.nih.gov/pubmed/34241740
http://dx.doi.org/10.1007/s10549-021-06316-2
work_keys_str_mv AT parkjihyun nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression
AT tacammoisesj nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression
AT chauhangaurav nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression
AT cohenevann nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression
AT gagliardimaria nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression
AT ileslakeslar nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression
AT uenonaotot nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression
AT battulavenkatal nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression
AT sohnyookyoung nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression
AT wangxiaoping nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression
AT kimhaksung nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression
AT krishnamurthysavitri nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression
AT fowlkesnataliew nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression
AT greenmorganm nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression
AT bartholomeuszgeoffreya nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression
AT tripathydebu nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression
AT reubenjamesm nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression
AT bartholomeuszchandra nonphosphorylatablepea15mutantinhibitsepithelialmesenchymaltransitionintriplenegativebreastcancerpartlythroughtheregulationofil8expression